logo.jpg
Helsinn closes financing agreement with BancaStato to support business objectives and growth
October 10, 2023 08:00 ET | Helsinn Healthcare S.A.
Helsinn closes financing agreement with BancaStato to support business objectives and growth New funding secured to expand the portfolio of late- and commercial-stage supportive care, oncology and...
logo.jpg
Helsinn announces publication of data evaluating impact of AKYNZEO® (fosnetupitant/palonosetron) on treatment outcomes and healthcare costs
June 12, 2023 09:00 ET | Helsinn Healthcare S.A.
Lugano, Switzerland, June, 12, 2023 - Helsinn Group (“Helsinn”), a fully integrated global biopharma company with a track record of over forty years of commercial execution and a strong focus in...
Helsinn announces pu
Helsinn announces publication of new data evaluating impact of NEPA (netupitant/palonosetron) on hospital costs
February 03, 2023 08:00 ET | Helsinn
Helsinn announces publication of new data evaluating impact of NEPA (netupitant/palonosetron) on hospital costs Lugano, Switzerland, February 3, 2023 - Helsinn Group (“Helsinn”), a fully integrated...
logo.jpg
Helsinn and Immedica enter exclusive partnership for commercialisation of cancer supportive care products in core European markets
January 24, 2023 03:00 ET | Helsinn Healthcare S.A.
Helsinn and Immedica enter exclusive partnership for commercialisation of cancer supportive care products in core European markets LUGANO, Switzerland and STOCKHOLM, Sweden – January 24, 2023 –...
logo.jpg
Helsinn closes financing agreement with Oberland Capital
January 10, 2023 08:00 ET | Helsinn Healthcare S.A.
Helsinn closes financing agreement with Oberland Capital Funding secured to expand the portfolio of late- and commercial-stage oncology and rare disease products through in-licensing or acquisitionDr...
logo.jpg
Helsinn announces the appointment of Dr Melanie Rolli as Group Chief Executive Officer
January 09, 2023 08:00 ET | Helsinn Healthcare S.A.
Helsinn announces the appointment of Dr Melanie Rolli as Group Chief Executive Officer - Giorgio Calderari appointed Vice Chairman of the Board Lugano, Switzerland, January 9, 2023 - Helsinn Group...
logo.jpg
Helsinn publishes results from a secondary analysis of a Phase 3 trial in patients with CINV Helsinn publishes results from a secondary analysis of a Phase 3 trial in patients with CINV
January 04, 2023 08:00 ET | Helsinn Healthcare S.A.
Helsinn publishes results from a secondary analysis of a Phase 3 trial in patients with CINV in The Oncologist Lugano, Switzerland, January 4, 2023 - Helsinn Group (“Helsinn”), a fully integrated...
logo.jpg
Helsinn announces presentation on CINV trial at European Society for Medical Oncology (ESMO) Asia
November 29, 2022 08:00 ET | Helsinn Healthcare S.A.
Helsinn announces presentation on CINV trial at European Society for Medical Oncology (ESMO) Asia Lugano, Switzerland, November 29, 2022 - Helsinn Group (“Helsinn”), a fully integrated global...
logo.jpg
Farma Mondo Group and Helsinn sign exclusive partnership to commercialize AKYNZEO® in the Baltic region
November 28, 2022 06:00 ET | Helsinn Healthcare S.A.
Farma Mondo Group and Helsinn sign exclusive partnership to commercialize AKYNZEO® in the Baltic region CHIASSO, Switzerland and LUGANO, Switzerland – November 28, 2022 – Farma Mondo Group, a...
logo.jpg
Helsinn publishes new data evaluating chlormethine gel’s mode of action in Dermatology and Therapy
October 18, 2022 08:00 ET | Helsinn Healthcare S.A.
Helsinn publishes new data evaluating chlormethine gel’s mode of action in Dermatology and Therapy Lugano, Switzerland, October 18, 2022 - Helsinn Group (“Helsinn”), a fully integrated, global...